Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.62 |
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | CA4 | P22748 | 2/20 | 0.62 |
| ▸ | CA6 | P23280 | 2/20 | 0.62 |
| ▸ | CA7 | P43166 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.62 |
| ▸ | CA3 | P07451 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | CA5A | P35218 | 1/20 | 0.62 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
| ▸ | TPMT | P51580 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL668540 | 0.90 | CA12 (0.69) | CA12CA1CA2CA4CA6 | |
| SCHEMBL801824 | 0.84 | LMNA (0.62) | CA12CA1CA2CA4CA6 | |
| SCHEMBL6915145 | 0.83 | TPMT (0.56) | CA12CA1CA2CA4CA6 | |
| SCHEMBL11521410 | 0.82 | CA12 (0.60) | CA12CA1CA2CA4CA6 | |
| SCHEMBL3355977 | 0.82 | TPMT (0.68) | CA12CA1CA2CA4CA6 | |
| SCHEMBL56960 | 0.82 | PTGS2 (0.72) | CA12CA1CA2CA4CA6 | |
| SCHEMBL18969524 | 0.82 | KMT2A (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13353970 | 0.82 | TSHR (0.54) | CA12CA1CA2CA4CA6 | |
| SCHEMBL3230514 | 0.82 | CA12 (0.78) | CA12CA1CA2CA4CA6 | |
| SCHEMBL17946064 | 0.82 | MEN1 (0.47) | CA12CA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230322675-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20220298163-A1 | BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BEIGENE, LTD. (KY) | 2022-09-22 | — | — | US | disclosed |
| US-11377449-B2 | BTK inhibitors with improved dual selectivity | BEIGENE, LTD. (KY) | 2022-07-05 | — | — | US | disclosed |
| US-11377449-B2 | BTK inhibitors with improved dual selectivity | BEIGENE, LTD. (KY) | 2022-07-05 | — | — | US | disclosed |
| US-20200181150-A1 | BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BEONE MEDICINES I GMBH (CH) | 2020-06-11 | — | — | US | disclosed |
| US-20200181150-A1 | BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BEONE MEDICINES I GMBH (CH) | 2020-06-11 | — | — | US | disclosed |
| CN-110997677-A | Btk inhibitors with improved dual selectivity | 百济神州有限公司 | 2020-04-10 | — | — | CN | disclosed |
| WO-2019034009-A1 | Btk INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BEIGENE, LTD. (KY) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034009-A1 | Btk INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BEIGENE, LTD. (KY) | 2019-02-21 | — | — | WO | disclosed |
| US-9193676-B2 | Method for producing compounds comprising nitrile functions | RHODIA OPERATIONS (FR) | 2015-11-24 | — | — | US | disclosed |
| US-20140350265-A1 | Method for producing compounds comprising nitrile functions | RHODIA OPERATIONS (FR) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298163-A1 | BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BTK, SYK, LYN | CA12 4675/4885CA1 4810/4885CA2 3319/4885 |
| US-20200181150-A1 | BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BTK, SYK, LYN | CA12 4675/4885CA1 4810/4885CA2 3319/4885 |
| US-20230322675-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LPAR2, LPAR1, LPAR6 | CA12 4342/4885CA1 4737/4885CA2 3842/4885 |
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LPAR1, LPAR2, LPAR5 | CA12 3655/4885CA1 3660/4885CA2 2116/4885 |
| US-11377449-B2 | BTK inhibitors with improved dual selectivity | BTK, SYK, LYN | CA12 4675/4885CA1 4810/4885CA2 3319/4885 |
| US-20140350265-A1 | Method for producing compounds comprising nitrile functions | IDH2, FASN, NOS2 | CA12 2594/4885CA1 3336/4885CA2 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.